Renalytix PLC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

OQB
UBS Group AG has filed an amendment to its Schedule 13G for Renalytix plc, primarily to correct the 'Date of Event Which Requires Filing of this Statement' to March 31, 2025.
OQB
UBS Group AG has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Renalytix plc, with its stake reduced to 0.0% as of the event date.
OQB
UBS Group AG has disclosed a 5.06% beneficial ownership stake in Renalytix plc, holding 16,774,708 ordinary shares, primarily due to its acquisition of Credit Suisse Group AG.